UPLOAD Filing
ADIAL PHARMACEUTICALS, INC.
Date: June 4, 2025 · CIK: 0001513525 · Accession: 0000000000-25-005907
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287679
Letter
Re: Adial Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 30, 2025 File No. 333-287679 Dear Cary Claiborne:
June 4, 2025
Cary Claiborne Chief Executive Officer Adial Pharmaceuticals, Inc. 4870 Sadler Road, Suite 300 Glen Allen, VA 23060
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Leslie Marlow, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> June 4, 2025 Cary Claiborne Chief Executive Officer Adial Pharmaceuticals, Inc. 4870 Sadler Road, Suite 300 Glen Allen, VA 23060 Re: Adial Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 30, 2025 File No. 333-287679 Dear Cary Claiborne: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Leslie Marlow, Esq. </TEXT> </DOCUMENT>